Taken together, these findings suggest that circulating PLIN2 reflects adiposity- and inflammation-related metabolic alterations in NAFLD and may serve as a promising non-invasive biomarker, particularly in combination with other clinical and laboratory parameters. The gene discussed is PLIN2; the disease is metabolic dysfunction-associated steatotic liver disease.